Cure My Disease

Don't miss your cure!

 Log in / Sign up

New RNA injection targets obesity and diabetes in early trial

NCT ID NCT06937203

Recruiting now Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 4 times

Summary

This early-stage study tests an experimental drug called ARO-ALK7 in 138 adults with obesity, some of whom also have type 2 diabetes. The drug is given as an injection and aims to help with weight loss and blood sugar control. The main goal is to check safety and how the body processes the drug, with some participants also receiving a standard diabetes medication (tirzepatide) alongside ARO-ALK7.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ARO-ALK7 (an experimental RNA-based drug given as an injection)
What this could lead to
If successful, this could point toward a new treatment for obesity and type 2 diabetes that helps with weight loss and blood sugar control.
What could go wrong
This is an early-phase trial (Phase 1/2a) focused on safety and dosing, so it's too soon to know if it works. Side effects are possible, and results may not lead to a final treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2 OBESITY

Contacts and locations

Locations

  • Research Site 1

    RECRUITING

    Auckland, 1010, New Zealand

  • Research Site 2

    RECRUITING

    Christchurch, 8011, New Zealand

  • Research Site 3

    RECRUITING

    Takapuna, Auckland, 0622, New Zealand

  • Research Site 4

    RECRUITING

    Rotorua, 3010, New Zealand

  • Research Site 5

    RECRUITING

    Grafton, Auckland, 1010, New Zealand

  • Research Site 6

    RECRUITING

    Papatoetoe, Auckland, 2025, New Zealand

  • Research Site 7

    NOT_YET_RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Research Site 8

    RECRUITING

    Morayfield, QLC, 4506, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.